<DOC>
	<DOCNO>NCT00558909</DOCNO>
	<brief_summary>The primary objective current study investigate safety tolerability BI 44847 male female patient type 2 diabetes follow oral administration repeat dos 100 mg b.i.d , 400 mg b.i.d . 800 mg b.i.d . 28 day . A secondary objective exploration pharmacokinetics pharmacodynamics BI 44847 multiple dosing , include assessment steady state .</brief_summary>
	<brief_title>4 Weeks Treatment Type II Diabetic Patients With BI 44847</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male postmenopausal hysterectomised female patient proven diagnosis type 2 diabetes mellitus treat diet exercise one 2 oral hypoglycaemic agent glitazones . In case 2 oral hypoglycaemic agent , least one may take 50 % maximum dose ; Age = &gt; 21 Age = &lt; 70 year ( female hysterectomised male patient ) ; Age = &gt; 55 Age = &lt; 70 year ( female postmenopausal patient ) ; BMI = &gt; 18.5 BMI = &lt; 40 kg/m2 ( Body Mass Index ) ; Signed date write informed consent prior admission study accordance GCP local legislation . Treatment insulin , glitazones , one oral hypoglycaemic agent ( except 2 agent least one take 50 % maximum dose ) ; Fasted blood glucose &gt; 240 mg/dl two consecutive day washout ; HbA1c &gt; 8.5 % screening ; Clinically relevant concomitant disease type 2 diabetes , hyperlipidaemia medically treated hypertension ; History relevant allergy/hypersensitivity ; Marked baseline prolongation QT/QTc interval ; History additional risk factor TdP ; Any laboratory value outside reference range clinical relevance acceptable opinion investigator , value 3 time high upper limit reference range ; Concomitant medication except acetylsalicylic acid , statin , antihypertensive ( diuretic allow ) , betablockers BPH occasional use paracetamol ( dose 1000 mg ; 2000 mg per day ; 2 day per week ) ; Change drug dosing allow comedication &lt; last 6 week ; Intake medication &lt; 5 halflives respective drug prior first administration study medication trial , except allow comedication ; Use drug might reasonably influence result trial prolong QT/QTc interval ( base knowledge time patient inclusion ) &lt; 10 day prior first administration study medication trial ; Use grapefruit ( juice ) &lt; 10 day prior first administration study medication trial ; Participation another trial investigational drug &lt; two month prior first administration study medication trial ; Smoker ; Inability refrain smoke specify trial day ; Alcohol abuse ; Drug abuse ; Blood donation ; Excessive physical activity ; Male patient use adequate contraception ; Women childbearing potential , positive pregnancy test lactating</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>